When UK-based GW Pharmaceuticals successfully convinced the FDA and the DEA to allow them to bring their cannabis-derived CBD isolate tincture to the U.S. market last year, surely some bottles got popped at the GW HQ as their anti-seizure medication, Epidiolex, stood unimpeded on a path to piles of cash.
READ MORE BELOW:
Source: http://bit.ly/2QBZsPg reposted by Cannabis News World . Original article by Beard Bros Crew
READ THE FULL STORY ON THE LINK BELOW
Source : UK | GW Pharma Denied Blanket Patent on Treating Epilepsy with Cannabinoids